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Summary
Background: Following breast cancer treatment recommendations, the conservative approach is accepted and highly 
respected in the Clinical Hospital Center (CHC) Rijeka. However, we have found that institutional follow-up data are lack-
ing. This retrospective analysis aims to update institutional data on survival and disease control rates.
Methods: From 2011 till 2014, 915 breast cancer patients underwent surgery at CHC Rijeka, and 615 were included in 
this analysis. The Institutional Ethics Committee approved the analysis.
Results: All patients were female, and the average age was 59 years. In the 5-year postoperative period, local, regional, 
and distant recurrence-free survival rates and overall survival and disease-free survival were calculated. All rates nega-
tively correlate with a higher T and N status and a higher stage of the disease. The analysis has also demonstrated that in 
the pT1-3 pN0-1 subgroup, sentinel lymph node biopsy (SLNB) was not inferior to axillary lymph node dissection (ALND) 
in terms of locoregional control of disease and overall survival.
Conclusion: Besides updating institutional data, the analysis confirmed that overall survival and locoregional control 
of the disease in the upfront-surgery patients are similar between pN0 and pN1 subpopulations and between pN2 and pN3, 
but statistically significantly different between pN0-1 and pN2-3. Currently ongoing, prospective observational multicenter 
clinical trial aims to translate the significance of these results into the neoadjuvant era.
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BACKGROUND
In the last few decades, there is a constant de-
escalation in the surgical approach to breast can-
cer (BC) patients. In all current guidelines, a con-
servative surgical approach is strongly recom-
mended for all early-stage BC patients. Following 
NSABP B-06 trial results (1), lumpectomy with 
whole breast radiation therapy (WBRT) became a 
standard of care for all T1-T2 BC patients, and due 
to the results of NSABP B-04 (2) and B-32 (3) trials, 
axillary lymph node dissection (ALND) was re-
placed with the sentinel lymph node biopsy 
(SLNB) in clinically node-negative (cN0) patients. 
Moreover, after the results of ACOSOG Z011 (4) 
and AMAROS (5) trial, ALND is no longer justi-
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fied, even in the case of pathologically node-posi-
tive (pN+) patients, considering that conservative 
breast surgery was made, WBRT would be con-
ducted, and that no more than two nodes were 
found to be involved with metastasis. However, 
for the high-risk pN+ patients, radiotherapy of the 
lymphatic drainage is highly recommended in-
stead of ALND.
In Clinical Hospital Center (CHC), Rijeka, all 
mentioned recommendations are accepted into 
clinical practice and are highly respected in every-
day work. However, in this era of conservative 
surgery, we have found that institutional and na-
tional follow-up data are lacking. Most of the re-
sults regarding survival and disease control cur-
rently come from randomized controlled trials, 
i.e., from the highly selected patients. The purpose 
of this retrospective analysis is to report our latest 
institutional updates on survival and disease con-
trol rates of unselected populations from the era of 
conservative surgical and adjuvant oncological 
approaches and to discuss the potential influence 
of these results translated into the present neoad-
juvant era.
PATIENTS AND METHODS
From 2011 till 2014, 915 female BC patients 
were surgically treated in CHC Rijeka. However, 
we excluded patients older than 80 years or with 
M1 status at the time of surgery, recurrent, bilat-
eral, or in situ disease, patients diagnosed with 
other malignant conditions, and those without 
follow-up data in the postoperative period. There-
fore, 615 patients remained for the analysis. All 
data used for this analysis were extracted from the 
integrated hospital informatics system of CHC Ri-
jeka with the approval of the Ethics Committee of 
CHC Rijeka.
Besides several T4 status patients, all patients 
were submitted to primary surgical treatment fol-
lowed with adjuvant oncological systemic and lo-
coregional treatment conducted according to the 
institutional protocol, i.e., according to the NCCN 
and St. Gallen’s consensus guidelines for that pe-
riod. In 283 cases (46.02%), lumpectomy and SLNB 
were performed, in 127 (20.65%) lumpectomy and 
ALND, in 34 (5.53%) mastectomy and SLNB, in 
164 (26.99%) radical mastectomy, and for four pa-
tients (0.65%) there was no data of surgical treat-
ment type. Axillary surgery was guided by NSABP 
B-32 (3), ACOSOG Z010 (6), ACOSOG Z011 (4), 
and AMAROS (5) trial criteria.
Overall survival (OS) rate is defined as a rate 
of patients surviving in 5 postoperative years or 
the last recorded control date. Distant disease-free 
survival or progression-free survival (DDFS or 
PFS) rate is defined as a rate of patients without 
evidence of distant metastasis, i.e., M1 status in 5 
postoperative years or at the date of the last re-
corded control. Local recurrence-free survival 
(LRFS) rate is defined as a rate of patients without 
evidence of disease in the already treated or con-
tralateral breast or thoracic wall in the five postop-
erative years or at the date of the last recorded 
control. Regional recurrence-free survival (RRFS) 
rate is defined as a rate of patients without evi-
dence of disease in the lymph nodes of unilateral 
or contralateral axilla, infraclavicular, supracla-
vicular, or internal mammary lymph nodes in 5 
postoperative years or to the date of the last re-
corded control. Disease-free, i.e., progression-free 
survival (DFS) rate is defined as patients’ rate 
without evidence of recurrence in 5 postoperative 
years or the date of the last recorded control. All 
rates are calculated by the method of Kaplan Mei-
er. The results are analyzed using Statistica 13 
software and interpreted at statistical significance 
p = 0.05. Clinical and pathological T, N, and stage 
of the disease are defined according to the 8th Edi-
tion of AJCC Cancer Staging Manual.
RESULTS
All patients were female, a mean age of 59 
years at the time of the surgery and in stage T1-4 
N0-3 M0 at the diagnosis time. The mean follow-
up time was 56.5 months (+/- 10.8 months, range 
from 4 to 60 months). Study population character-
istics and outcomes are displayed in Table 1.
Overall local, regional, and distant recur-
rence rates and overall survival and disease-free 
survival rates in 5 postoperative years are calcu-
lated by Kaplan Meier’s method and displayed in 
Figure 1.
Furthermore, all rates are calculated in cor-
relation with immunophenotype, T and N status, 
stage of the disease, and surgical treatment type. 




Study population characteristics and the outcomes in terms of overall survival (OS), distant (DRFS), local (LRFS), and regional 
recurrence-free survival (RRFS) in the five years postoperatively.
Patients
OS/5y DRFS/5y LRFS/5y RRFS/5y












































































































































































































































































































































































































































































































































































































































Table Legend: Immunophenotype is defined according to 2013 St. Gallen consensus [7], TNBC=Triple negative breast cancer, N=number, OS/5y=5 years overall survival, 
DRFS/5y= 5 years disease-free survival, LRFS/5y=5 years local recurrence-free survival, RRFS/5y=5 years regional recurrence-free survival, pathological T, N and stage of the 
disease are defined according to current TNM classification by 8th Edition AJCC Cancer Staging Manual, BCS=breast conserving surgery (lumpectomy), SLNB=sentinel 
lymph node biopsy, M=mastectomy and ALND=axillary lymph node dissection.
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As expected, survival rates are decreasing 
with the higher T and N status on the pathology 
report and a higher stage of the disease. However, 
OS, LRFS, and RRFS rates are not statistically sig-
nificantly different between pN0 and pN1 and be-
tween pN2 and pN3, but among these two groups, 
the statistically significant difference is recorded.
All rates are also calculated for the pT1-3 
pN0-1 subgroup concerning the extent of axillary 
surgery, demonstrating that SLNB is not inferior 
to ALND in terms of disease control (DFS, DDFS, 
LRFS, RRFS) and overall survival for this subpop-
ulation of BC patients.
DISCUSSION AND CONCLUSION
Development of novel anticancer drugs and 
increasing trend of neoadjuvant oncological ap-
Figure 1. 5 years overall survival rate (95.93%), disease-free survival rate (85.85%), distant disease-free survival rate (90.08%), local 
recurrence-free survival rate (95.12%), and regional recurrence-free survival rate (96.26%) for the whole cohort, calculated by the 
method of Kaplan Meier
Table 2.
Correlation of survival rates with immunophenotype, T, N, and stage of the disease are calculated, and the test results (Chi-square) 
with the associated p-values are displayed for each correlation.
Test statistic OS DFS DDFS LRFS RRFS
Immunophenotype Chi-square 27.051 37.359 26.978 30.577 7.062
p-value 0.00002 0.00000 0.00003 0.00000 0.13260
T status Chi-square 20.418 49.996 50.579 17.095 16.036
p-value 0.00004 0.00000 0.00000 0.00068 0.00112
N status Chi-square 30.050 73.528 72.197 12.319 27.290
p-value 0.00000 0.00000 0.00000 0.00637 0.00001
Stage of disease Chi-square 34.679 73.267 70.774 20.419 25.838
p-value 0.00001 0.00000 0.00000 0.00234 0.00024
Except for the RRFS, all rates are statistically significantly correlated to cancer immunophenotype as well as with T status, N status, and the stage of the disease.
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proach for operable BC are leading to even less 
surgery. Several ongoing trials (8,9,10) aim for 
more de-escalation of axillary surgery for early BC 
patients in the primary-surgery setting.
Besides updating our institutional data, we 
have demonstrated that pT4 status, pN2-3 status, 
and stage above IIIB are related to the worst onco-
logical outcome in the primary surgery era. The 
analysis also indicates that pN0 and pN1 patients 
have similar outcomes in terms of OS and locore-
gional control of disease and the pN2 and pN3 pa-
tients, but there is a statistically significant differ-
ence between pN0-1 and pN2-3 subgroups.
Moreover, according to our data, the extent 
of axillary surgery is not related to those outcomes 
in early and locally advanced (pT1-3 pN0-1) BC 
patients.
What might be the significance of these re-
sults translated in the neoadjuvant era? It is well 
known that preoperative systemic treatment does 
not affect OS and DFS for the whole cohort (11) 
but significantly improves the outcome of good 
responders to NAT.
The prospective observational multicenter 
trial, currently ongoing (12), is aiming to deter-
mine if there will be an improvement of survival 
rates of cN2 patients converted to ycN0 following 
NAT as well as the oncological safety of the ALND 
omission after SLNB, for initially cN1-2 patients 
converted to ypN0(sn) after NAT, in terms of over-
all survival and locoregional disease control.
Despite the reduced extent of axillary sur-
gery, we do not expect worse oncological out-
comes. Herein presented institutional data would 
provide the foundation for all anticipated compa-
rations.
In addition, two ongoing randomized con-
trolled trials, NEONOD II (13) and ATNEC (14), 
are yet another step ahead and are currently in-
vestigating if cN1 patients, converted to ypN+ fol-
lowing NAT, but with minimal residual disease in 
the axilla, could be safely spared of ALND with or 
without radiotherapy to the lymphatic drainage, 
i.e., investigating if the results of ACOSOG Z010 
(6), IBCSG 23-01 (15) and AMAROS (5) trial re-
sults can be safely translated into the neoadjuvant 
setting.
Although ypN+ signifies the resistance to the 
systemic treatment, based on our analysis, we 
strongly believe in the trials mentioned above’ 
positive outcomes and in the safe translation of 
conservative axillary surgery into the neoadjuvant 
setting.
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Table 3a and 3b:
Overall survival, local recurrence-free survival, and regional 
recurrence-free survival according to the N status; between N0 
and N1, as well as between N2 and N3, we have found no 
statistically significant differences (3a), but we have found a 
significant difference in prognosis between N0-1 and N2-3 (3b).
Table 3a N0 N1 N2 N3
OS 98.11% 97.97% 89.66% 82.86%
LRFS 96.23% 96.62% 87.93% 88.57%
RRFS 97.84% 97.97% 87.93% 85.71%
Table 3b N0-N1 N2-N3 Log-Rank test p-value
OS 98.07% 87.10% -5.39 0.00000
LRFS 96.34% 88.17% -3.50 0.00046
RRFS 97.88% 87.10% -5.17 0.00000
Table 4.
Survival rates for T1-3 N0-1 subpopulation correlate to the 
extent of axillary surgery; the extent of axillary surgery is not 
related to overall survival and locoregional control of the disease 
in this subpopulation of breast cancer patients.
SLNB ALND Log-Rank test p-value
OS 99.04% 96.11% -2.27 0.02305
DFS 93.93% 86.67% -2.79 0.00520
DDFS 97.12% 90.00% -3.43 0.00060
LRFS 96.49% 96.67% 0.05 0.95813
RRFS 98.08% 97.22% -0.67 0.50231
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OPERABILNI INVAZIVNI KARCINOM DOJKE U ERI KONZERVATIVNE KIRURGIJE;  
RETROSPEKTIVNA ANALIZA 5-GODIŠNJEG PREŽIVLJENJA I KONTROLE BOLESTI
A. Car Peterko, M. Avirović, I. Skočilić, P. Valković Zujić, I. Belac Lovasić i F. Lovasić
Uvod: Temeljem suvremenih preporuka za liječenje karcinoma dojke, u Kliničkom bolničkom centru (KBC) Rijeka 
prihvaća se i zagovara konzervativni kirurški pristup. Međutim, na razini naše institucije, ali i na nacionalnom nivou, malo 
je obrađenih rezultata liječenja. Cilj ove retrospektivne analize je ažuriranje institucionalnih podataka o preživljenju i 
 kontroli bolesti.
Metode: U periodu od 2011. do 2014. godine, u KBC Rijeka operirano je 915 pacijentica oboljelih od karcinoma dojke, a 
njih 615 uključeno je u ovu analizu. Istraživanje je odobreno od Etičkog povjerenstva KBC Rijeka.
Rezultati: Sve su pacjentice bile žene, prosječno stare 59 godina. Izračunate su ukupne stope preživljenja bez lokalnog, 
regionalnog i udaljenog recidiva, te stope ukupnog preživljenja i preživljenja bez povrata bolesti u petogodišnjem postope-
rativnom periodu. Sve su stope u negativnoj korelaciji sa višim T i N statusom kao i višim stadijem bolesti. Osim navedenog, 
rezultati su potvrdili da je biopsija sentinel limfnog čvora ekvivalentna aksilarnoj disekciji u smislu lokoregionalne kontrole 
bolesti kao i ukupnog petogodišnjeg preživljenja u pT1-3 pN0-1 podskupini.
Zaključak: Osim ažuriranja podataka naše institucije, ova je analiza potvrdila da su stope preživljenja i lokoregionalne 
kontrole bolesti u eri primarnog kirurškog tretmana slične između pN0 i pN1 subpopulacija kao i među pN2 i pN3, među-
tim statistički značajno različite između pN0-1 I pN2-3 podskupina. Prospektivno, opservacijsko, multicentrično kliničko 
istraživanje koje je u tijeku pokušava istražiti značenje ovih rezultata u neoadjuvantoj eri.
KLJUČNE RIJEČI: karcinom dojke, preživljenje, recidiv
